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Investigation of the cytotoxic potential of methyl
imidazole-derived thiosemicarbazones and their
copper(II) complexes with dichloroacetate as
a co-ligand†
Oleg Palamarciuc,a Miljan N. M. Milunovic´, *bc Angela Sıˆrbu,a Elena Stratulat,a
Aurel Pui,d Nevenka Gligorijevic,e Sinisa Radulovic,e Jozef Kozˇı´sˇek,c
Denisa Darvasiova´,c Peter Rapta,c Eva A. Enyedy, f Ghenadie Novitchi,g
Sergiu Shovah and Vladimir B. Arion *b
A series of six imidazole-derived thiosemicarbazones (HL1–HL6) and their copper(II) complexes (1–6)
were synthesised and characterised by analytical, spectroscopic, electrochemical and single crystal X-ray
diffraction techniques. In addition, solution studies and the results of antiproliferative activity in human cancer
cell lines with some insights into the mechanism of cancer cell death are also reported. In particular, the
substitution of one hydrogen at the terminal N-atom of the thiosemicarbazide moiety by a phenyl group
resulted in slightly enhanced antiproliferative activity. HL3 and HL6 showed lower IC50 values compared
to HL1 and HL4 in MDA-MB-453 and LS174 cancer cell lines. The copper(II) complexes 3 and 6 exhibit a
2.4- and 4.7-fold increase of activity compared to parent proligands in MDA-MB-453 cancer cell line,
respectively. The complex formation of the proligands with copper(II) increased their antiproliferative activity
in all investigated cell lines. The cell cycle perturbations, apoptotic potential and the analysis of morphological
changes in the A549 cell line induced by 3 and 6 revealed cytostatic rather than cytotoxic effects.
1 Introduction
The thiosemicarbazide moiety is a key pharmacophore of many
agents with anticancer activity. The most studied thiosemi-
carbazide derivative so far is 3-aminopyridine-2-carboxaldehyde
thiosemicarbazone (Triapine). Despite its remarkable cytotoxic
activity in vitro and in vivo, clinical investigations showed mixed
results.1–5 Recently, two thiosemicarbazones (TSCs) of a new
generation, namely di-2-pyridylketone 4-cyclohexyl-4-methyl-3-
thiosemicarbazone (DpC) and (E)-N0-(6,7-dihydroquinolin)-
8((5H)-ylidene)-4-(pyridine-2-yl)piperazine-1-carbothio-hydrazide
(COTI-2), have entered clinical studies, rekindling the interest
for this class of compounds.6,7 Regardless of their broad bio-
logical/pharmacological potency and multitarget features, TSCs
act as excellent metal chelators, often exhibiting enhanced
biological activity upon coordination to metal ions.8
Copper, as an essential micronutrient in the human body,
plays an important role in metabolic processes (oxygen transport,
cell signaling and enzyme activity).9 Besides its biological
importance, copper increases the cytotoxic eﬀect of many thio-
semicarbazones upon coordination.10–13 Copper(II)-thiosemi-
carbazonates exhibit remarkable antiproliferative activity in
various cancer cell lines,10,11,13 inhibit the topoisomerase II
enzyme14,15 and/or induce apoptosis.13
The mechanism of action of copper(II)-thiosemicarbazonates
is often closely related to apoptosis caused by (i) the inhibition
of the important enzymes often overexpressed in cancer cells,
(ii) formation of free radicals (reactive oxygen species (ROS))
due to the redox activity of copper, which damage important
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biomolecules (enzymes, DNA) and (iii) DNA intercalation.13,16–18
Neutral and cationic copper(II) bis(thiosemicarbazone) complexes
with methyl and phenyl substituents caused DNA cleavage and
inhibition of topoisomerase II and inhibited tumour growth when
administered in vivo.19
The imidazole moiety is imbedded into the structures of
important biological compounds (e.g., histidine) and it is a
central pharmacophore in many antiviral, antifungal and anti-
cancer agents.20 Recent studies on imidazole-derived thiosemi-
carbazones showed an antiproliferative eﬀect on bacteria,
which is enhanced upon coordination to copper(II). Polyphar-
macological eﬀects, e.g., cytotoxic and antimicrobial activity,21
were also noticed for other compounds.22
Dichloroacetic acid (DCA) interrupts mitochondrial function
by inhibiting pyruvate dehydrogenase and does not have a toxic
eﬀect on normal cells.23 At the same time DCA exhibits
antiproliferative activity in T-cell lymphoma,24 small-cell
lung,25 prostate,26 colorectal27 and breast carcinoma cells,28
when applied separately or in combination with other approved
chemotherapeutics such as platinum-based drugs,29 5-fluoro-
uracil,30 bortezomib,31 sorafenib,32 and bevacizumab.33 Quite
recently, DCA entered phase I clinical trials as a potential
agent against brain tumours upon oral administration.34
A copper(II) thiosemicarbazonate co-crystallised with DCA was
reported as an eﬀective antiproliferative agent against breast
cancer cells.35
A fusion of dichloroacetate with copper(II) complexes based
on imidazole-carboxaldehyde thiosemicarbazone in one com-
pound might be of interest for the development of dual-action
anticancer drugs.
Herein we report on the synthesis and characterisation of
methyl imidazole-derived thiosemicabazones HL1 and HL4 and
their N-methyl and N-phenyl substituted analogues HL2, HL3,
HL5 and HL6 as shown in Chart 1, as well as of their copper(II)
complexes 1–6 with dichloroacetate as a co-ligand, shown in
Chart 2.
In addition, complex formation with copper(II) in solution,
the electrochemical behaviour of the copper(II) complexes and
the antiproliferative activity of proligands HL1–6 and their
copper(II) complexes 1–6 in human lung adenocarcinoma
cells (A549), colon cancer cells (LS174), breast carcinoma cells
(MDA-MB-453) and human bronchial epithelial cells (BEAS-2B)
were investigated. Finally, the apoptotic potential and the
mechanism of cell demise of the most active complexes 3 and
6 in lung adenocarcinoma cells (A549) are reported.
2 Results and discussion
2.1 Synthesis and characterisation of proligands HL1–6 and
the copper(II) complexes 1–6
All proligands were obtained in high yields by a condensation
reaction of 2-methyl-1H-imidazole-4-carboxaldehyde or 5-methyl-
1H-imidazole-5-carboxaldehyde with thiosemicarbazide or its
N4-substituted derivative in absolute ethanol under reflux. The
products were characterised by elemental analyses, which were
in agreement with expected compositions, ESI mass spectro-
metry, one- and two-dimensional NMR spectroscopy, UV-vis and
IR spectroscopy. Positive ion ESI mass spectra showed peaks
with m/z values attributed to [HL + H]+ and [HL + Na]+ ions,
Chart 1 Synthesis and line drawings of proligands HL1–6. Reaction conditions: EtOH, reflux, 2 h. The atom labelling is used for NMR resonance
assignment.
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namely 184 and 206 for HL1 and HL4, 198 and 220 for HL2 and
HL5, and 260 and 282 for HL3 and HL6, while in negative ion
mode spectra peaks with m/z 182 attributed to [L1] and [L4],
196 to [L2] and [L5], and 258 to [L3] and [L6] were observed.
The existence of E and Z isomers in solution was confirmed
by two sets of signals in 1D (1H and 13C) and 2D (COSY, HSQC,
HMBC) NMR spectra in (CD3)2SO (see ESI†). Geometric isomerism
is typical for thiosemicarbazones and our data are in good
agreement with those reported for other imidazole-thiosemi-
carbazones.36–40 The population ratio is 1 : 1 for all proligands
in (CD3)2SO reflecting the statistical distribution of E and
Z isomers, except HL2, for which the Z isomer is favoured
(Z :E = 1 : 0.26). It should be also noted that isomerisation
is accompanied by proton exchange processes (involving DHO
present in (CD3)2SO). These exchange processes strongly affect the
relaxation times of particular nuclei and, as a consequence, some
13C signals were not detected. More affected are the Z isomers
implying their higher lability when compared to the E isomers.
Additionally, significant differences in chemical shifts (up to
B1 ppm) for the imine protons were observed (see ESI†). The
higher lability of Z over E isomers, along with the large difference
in the chemical shifts for some protons, indicates not only Z/E
isomerism in solution, but also the acid–base tautomerism of
imidazole rings as depicted in Chart 3 for HL1.
The copper(II) complexes 1–6 were obtained by reaction of
an appropriate thiosemicarbazone with Cu2(OH)2CO3 and
dichloroacetic acid in a 2 : 1 : 2 molar ratio in aqueous ethanol
under reflux. Green raw products, separated from solution
upon standing at room temperature within 3–4 days, were
re-crystallised in ethanol. The compounds were characterised
by UV-vis, IR spectroscopy and ESI mass spectrometry. Electronic
absorption spectra showed characteristic intraligand bands with
maxima between 300 and 380 nm and metal-to-ligand charge
transfer and d–d transition (low extinction coefficients) bands in
the range 550–750 nm (see ESI,† Fig. S8). ESI-MS measurements
in positive ion mode showed peaks attributed to ions [CuII(L1–6)]+
and [CuII2 (L
1–6)2(CHCl2CO2)]
+, while in negative ion mode peaks
with m/z values (see Experimental section) which could be
assigned to ions [CuII(L1–6–H)(CHCl2CO2)]
 and [CuII2 (L
1–6–H)2-
(CHCl2CO2)]
. ESI mass spectra of a methanolic solution of 6
with an excess of DMSO measured immediately after sample
preparation showed a major peak at m/z 771 assigned to
[CuII2 (L
6)2(CHCl2CO2)]
+ and a minor peak at m/z 399 which
can be attributed to [Cu(L6)DMSO]+. The general picture did
not change after 24 h, indicating that replacement of the
dichloracetato co-ligand (CHCl2CO2
) by DMSO is not time-
dependent and a favoured transformation (see ESI†). The
compounds crystallised in ethanol proved to be suitable for
single crystal X-ray crystallography studies.
2.2 X-ray crystallography (description of the crystal structure
of 1–6)
The results of X-ray diﬀraction studies of 1–6 are shown in
Fig. 1 and 2, while bond distances and bond angles are quoted
in Tables S1–S7 (ESI†). All six compounds have an ionic
crystal structure, which is built up from the complex cations
[Cu(HL1–6)(CHCl2CO2)]
+ and dichloroacetate counteranion in
1 : 1 stoichiometry (Fig. 1 and 2). There are no co-crystallised
solvent molecules in 1, 3 and 4, while 2, 5 and 6 crystallise
with one water or ethanol molecule per copper(II) complex.
Chart 2 Line drawings of copper(II) complexes 1–6. Dichloroacetate as a counteranion and co-crystallised ethanol molecules were omitted for the sake
of clarity.
Chart 3 Geometric E/Z isomerism, tautomerism of the imidazole ring
and H-bonding interactions in HL1.
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The thiosemicarbazones HL1–6 in the structures 1–6 act as
neutral tridentate ligands and bind to copper(II) via NNS donor
atoms. In complexes 1, 4 and 5 the copper(II) ion adopts a
slightly distorted square-planar coordination geometry, which
is completed by monodentate binding of the CHCl2CO2
 anion.
The coordination environment of the copper(II) atom in 2, 3
Fig. 1 Extended asymmetric unit and coordination environment around the Cu(II) ion in 1, 2 and 3 with atom labelling and thermal ellipsoids at 50%
probability level. H-Bond parameters for 1: N4–H  O3 [N4–H 0.88 Å, H  O3 1.76 Å, N4  O3 2.615(2) Å, N4–H  O3 165.11]; N5–H  O4 [N5–H 0.88 Å,
H  O4 2.02 Å, N5  O4 2.895(2) Å, N5–H  O4 174.71]. Symmetry code: (i) 1  x, y, z. H-Bond parameters for 2: O1w–H1w  O3 [O1w–H 0.82 Å,
H1w  O3 1.99 Å, O1w  O3 2.790(2) Å, O1w–H1w  O3 165.21]; O2w–H2w  O1 [O2w–H2w 0.83 Å, H2w  O1 2.00 Å, O2w  O1 2.825(19) Å,
O2w–H2w  O1 170.91]. H-Bond parameters for 3: N4–H  O4 [N4–H 0.88 Å, H  O4 1.81 Å, N4  O4 2.688(3) Å, N4–H  O4 175.11]; N5–H  O5
[N5–H 0.88 Å, H  O5 1.88 Å, N5  O5 2.763(3) Å, N5–H  O5 175.91].
Fig. 2 Extended asymmetric unit and coordination environment of copper(II) in 4–6 with atom labelling and thermal ellipsoids at 50% probability level.
H-Bond parameters for 4: N4–H  O3 [N4–H 0.88 Å, H  O3 1.76 Å, N4  O3 2.638(2) Å, N4–H  O3 173.21]; N5–H  O4 [N5–H 0.88 Å, H  O4 1.97 Å,
N5  O4 2.800(2) Å, N5–H  O4 168.61]. Symmetry code: (i) x, 1  y, 1  z. H-Bond parameters for 5: N4–H  O4 [N4–H 0.88 Å, H  O4 1.84 Å,
N4  O4 2.701(2) Å, N4–H  O4 164.91]; N5–H  O3 [N5–H 0.88 Å, H  O3 1.88 Å, N5  O3 2.761(2) Å, N5–H  O3 177.11]. Symmetry code: (i) 1  x, 1  y,
1  z. H-Bond parameters for 6: N4–H  O3 [N4–H 0.88 Å, H  O3 1.82 Å, N4  O3 2.693(2) Å, N4–H  O3 171.21]; N5–H  O4 [N5–H 0.88 Å,
H  O4 1.92 Å, N5  O4 2.785(2) Å, N5–H  O4 165.51]; N2–H  O5 [N2–H 0.88 Å, H  O5 1.88 Å, N2  O5 2.746(2) Å, N2–H  O5 166.51]. Symmetry
code: (i) 1  x, y, 2  z.
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and 6 is five-coordinate and can be described as distorted
square-pyramidal. In addition to the tridentate ligands HL2,
HL3 and HL6 in 2, 3 and 6, the central copper(II) atom is bound
by the monodentate CHCl2CO2
 anion in the base of the
pyramid and by a C2H5OH or H2O molecule in the apical
position (Fig. 1 and 2).
The displacement of the Cu(II) ion from the basal plane
towards the apical position is equal to 0.269, 0.153 and 0.129 Å,
for 2, 3 and 6, respectively. Selected bond distances, showing
the geometry of the coordination environment, are given in
Table S1 (ESI†). It is of note that the copper(II) in all complexes
(except 2 and 3) is additionally coordinated by a donor atom
from an adjacent unit with formation of a centrosymmetric
dinuclear cationic species (Fig. 1, 2 and Fig. S1–S6, ESI†) with
a Cu  Cu0 separation of 3.619(2) Å, 3.445(2) (molecule A) and
3.5443(2) Å (molecule B), 3.5320(2) Å and 3.9659(1) Å for 1, 4, 5
and 6, respectively. In two cases (1 and 6), additional coordina-
tion or weak interaction is provided by the sulfur atom of
the thiosemicarbazide moiety with a Cu1  S10 distance of
2.8274(2) Å and 3.2035(9) Å for 1 and 6, respectively, and by
the oxygen atom from the coordinated CHCl2CO2
 anion in 4
(Cu1  O0 2.5134(2) Å (for molecule A) and 2.5240(2) Å (for
molecule B)) and in 5 (Cu1  O0 2.5244(1) Å). Of note is the
formation of dimeric associates in 1 through the thioamide S
atoms of neutral HL1.41 The building of such dimers is more
common for copper(II) complexes with anionic (iminothiolate)
thiosemicarbazonato ligands.42,43 The packing of the studied
complexes is determined by intermolecular hydrogen bonding
interactions due to the presence of various proton-donors,
e.g., NH groups of imidazole and thiosemicarbazide moieties,
and proton-acceptor groups, e.g. OH, provided by coordinated
solvent molecules. In particular, the formation of 2D supra-
molecular architectures is of note in the majority of complexes
except crystal 2, which shows the formation of a rather elaborate
3D supramolecular network, and 5, the crystal structure of which
is characterized as the packing of isolated supramolecular
ribbons. Views of parts of the crystal structure for 1–6 are shown
in Fig. S9–S14 (ESI†), respectively.
The thermodynamic stability of the complexes characterised
in the solid state by X-ray crystallography was further investigated
in aqueous solution.
2.3 Solution equilibrium studies (protonation of proligands
HL1 and HL4 and copper(II) complex formation)
In order to characterise the protonation/proton dissociation
of proligands HL1 and HL4, as well as copper(II) complex
formation with HL1 and HL4 as ligands, UV-vis spectrophoto-
meric titrations were performed by using aqueous solutions.
The measured spectra revealed characteristic changes in the
monitored wavelength range upon increasing the pH, especially
in the basic pH range (see Fig. 3 for HL1). The pH-dependence
of the absorbance values showed two well-separated deprotona-
tion steps at pH 4.2–7.0 and 10.0–12.2 for both proligands
studied. Therefore, two protonation constants (pKa values)
could be determined on the basis of the deconvolution of the
measured spectra (Table 1).
The protonated proligands possess two proton dissociable
groups, namely the imidazole N2
0
H+ and the hydrazine N4
0
–H
of the thiosemicarbazide moiety. pK1 and pK2 can be attributed
to the deprotonation of the imidazole and the hydrazine
nitrogens, respectively. Notably, the negative charge is mainly
localised on the S atom in the deprotonted (L1) or (L4) forms
via the thione/thiol tautomeric equilibrium as shown in
Chart 4. The values of pK2 are rather uncertain as the second
deprotonation step takes place partly in the pH range where the
measurement of pH became less accurate (pH 4 11.5) due to
the alkaline error of the glass electrode. The calculated
individual spectra of the proligand species (shown for HL1
in Fig. 3) present strong similarity between the absorption
of species H2L
+ and HL, while spectra of HL and L are
significantly different. The pKa values of proligands HL
1 and
HL4 are similar to each other, although pK1 is somewhat lower
for HL4. pKa values of the best-known a-N-pyridyl thiosemi-
carbazone, triapine, were reported in our previous work only in
Fig. 3 UV-vis spectra of HL1 recorded in the pH range 2–12.2. Inset
shows the calculated molar absorbance spectra of the proligand species in
the different protonation states (cligand = 49 mM; I = 0.10 M (KCl); T = 298 K).
Table 1 Protonation (log b HiL) and proton dissociation constants (pKa) of
the ligands HL1 and HL4, lmax and molar absorptivity (e) values of the ligand
species and conditional (log b4.070 [CuL]
+) and overall stability constants
(log b [CuL]+) of the copper(II) complexes (I = 0.10 M (KCl); T = 298 K)
Proligand HL1 HL4
log b HL 11.6  0.1 11.6  0.1
log b H2L
+ 17.19  0.04 16.89  0.04
pK1 5.64 5.34
pK2 11.6 11.6
lmax, nm (e, M
1 cm1) H2L
+ 302 (2.70  104) 302 (2.98  104)
lmax, nm (e, M
1 cm1) HL 304 (2.50  104) 308 (2.95  104)
lmax, nm (e, M
1 cm1) L 328 (1.49  104) 332 (1.85  104)
log b0 [CuL]+ at pH 4.07a 8.6  0.1 8.88  0.06
log b [CuL]+ b 17.6 17.65
a Determined by UV-vis spectroscopy via competition studies with
EDTA. Protonation constants of EDTA and stability constants of its
copper(II) complex are taken from the literature.45 log b values:
10.26 (HL), 16.42 (H2L), 19.09 (H3L), 21.08 (H4L), 18.7 (CuL). log b0 of
(CuL): 10.40 at pH 4.07. b Calculation of the overall stability constants
of the [CuL]+ complexes (b) from the conditional stability constants
(b0 at pH 4.07): b = b0  aH, where aH = 1 + [H+]  bHL + [H+]2  bH2L+;
[H+] = 104.07.
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the presence of 30% (w/w) DMSO.44 However, data obtained in
different media cannot be compared directly. Nevertheless, the
undoubtedly higher pKa of the hydrazine nitrogen in the
studied herein proligands HL1 and HL4 (Table 1) compared to
that of triapine (10.78) is obvious. In addition, the pKa of the
imidazole nitrogen is also higher than that of the pyridinium
nitrogen in triapine (3.92). Based on the determined pKa values
it can be concluded that both proligands, and most probably
the other derivatives studied herein as well, are present in their
neutral HL form at physiological pH.
The complex formation with copper(II) is well-indicated by
the development of the characteristic S - Cu charge transfer
band with a maximum at 321 and 327 nm in the case of HL1
and HL4 (Fig. 4a), respectively. The absorbance values at these
wavelengths show pH-dependence most probably due to the
protonation of the complex at the hydrazine nitrogen in the
acidic pH range and due to the formation of mixed hydroxido
complexes in the basic pH range, as it was found for copper(II)
complexes of numerous a-N-heterocyclic thiosemicarbazones,
e.g., triapine or 2-formylpyridine TSC, or further deprotonation
of the thiosemicarbazone.38,44 The latter is supposed to take
place only under the conditions of ESI MS measurements
(see Experimental). The titration data indicate that the optimal
window for the complex formation between HL1 or HL4 and the
metal ion resulting in [CuL]+ type species is between pH 3.3 and
4.5. First, methods of continuous variation (Fig. 4b) and molar
ratios were applied to establish the stoichiometry and stability
of the complex formed. The data suggest building of 1 : 1
complexes (as there was no indication for the formation of
bis-ligand to metal complexes at ligand excess), which is
practically quantitative under the applied conditions (pH 4.07).
This latter finding hindered the direct determination of the
apparent (conditional) formation constants (b0) of the copper(II)
complexes.
In order to determine the b0 values for the [CuL]+ complexes,
competition reactions with EDTA were performed at pH 4.07
using spectrophotometry (Fig. 5). It should be noted that EDTA,
its copper(II) complex and the unbound TSC ligand have
negligible contribution to the measured absorbance values at
the chosen wavelengths, namely 337 nm for HL1 and 340 nm
for HL4.
The determined conditional formation constants are quoted
in Table 1. These constants are fairly similar to each other.
Chart 4 Deprotonation steps of (H2L
1)+.
Fig. 4 Changes of UV-vis spectra of HL4 (solid line) (a) upon addition of 1 equiv. of Cu(II) (dashed line) at a constant pH (pH = 3.75; cligand = 38.7 mM);
(b) dependence of absorbance values at 340 nm vs. ratio of cligand to cligand + cCu(II) at a constant pH and constant cligand + cCu(II) (pH = 4.07; cligand +
cCu(II) = 100 mM).
Fig. 5 Concentration distribution for the Cu(II)–HL4–EDTA system at pH
4.07 at various EDTA concentrations together with the recorded absor-
bance values at 340 nm (cligand = 50 mM; cCu(II) = 50 mM; cEDTA = 0–70 mM;
I = 0.10 M (KCl); T = 298 K).
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The constant for [Cu(L4)]+ is slightly higher than that of
[Cu(L1)]+. By using the protonation constants of the proligands
the overall stability constants (b) of the complexes [CuL]+ could
be also calculated from the conditional stability constants
determined (Table 1). These constants reflect the formation
of high stability copper(II) complexes with a-N-imidazole-
carboxaldehyde thiosemicarbazones used in this study. UV-vis
spectra for the copper(II)–HL1 (or HL4) systems were recorded
in a wide concentration range (10 to 100 mM) and the observed
linear dependence (see Fig. S15, ESI,† for HL1) indicates
the high solution stability of the metal complexes at the
studied pH.
2.4 Electrochemistry
Cyclic voltammograms of 1–6 measured in DMSO/nBu4NPF6
using a Pt working electrode are very similar to each other and
show one reduction peak and a strongly shifted reoxidation
peak at a scan rate of 100 mV s1 as shown for 4–6 in Fig. 6 and
1–3 in Fig. S16 (ESI†). The first reduction step is supposed to be
metal-centred and can be attributed to the CuII- CuI process.
The cathodic peak potentials Epc of 4–6 are 0.83 V, 0.83 V,
and 0.86 V vs. Fc+/Fc (0.19 V, 0.19 V, and 0.22 V vs. NHE),
respectively. These low redox potentials clearly occur within the
biologically accessible window (0.4 to +0.8 V vs. NHE) using
the known E1/2 of ferrocene (+0.64 V) versus the standard
hydrogen electrode (SHE).46
A large peak-to-peak separation (around 600 mV) indicates
a slow electron transfer. This was confirmed by experiments at
diﬀerent scan rates (Fig. 7), where by decreasing the scan rate
the peak-to-peak separation decreases.
As can be seen in Fig. 7c the peak current for the electro-
chemical reduction of 6 shows a linear dependence vs. the
square root of the scan rate, indicating a diﬀusion controlled
reduction process.47,48 However, the dependence of the anodic
peak current vs. the square root of the scan rate is not linear
(Fig. 7d). The successful simulation of the corresponding
cyclic voltammograms confirmed the slow electrode kinetics
(ks = 0.9  105 cm s1) and adsorption of the less soluble
reduced CuI species (Gmax = 3.7  109) on the electrode
surface.49–51 An example of simulated CV is shown for 6 in
Fig. S17 (ESI†). In addition, the simulation enabled the deter-
mination of the formal redox potential for 6 with E10 = –0.48 V
vs. Fc+/Fc (see Table S8, ESI†).
These studies indicate that potentially compounds 1–6 can
be reduced by biological reductants and generate ROS under
the conditions of MTT assays, which often induce apoptosis
of cancer cells by damaging DNA52 or other biomolecules53
as reported for related thiosemicarbazones. The reduction of
Cu(II) to Cu(I) for complexes with redox potentials in a bio-
logically relevant window is feasible. The reoxidation of Cu(I)
with molecular oxygen could lead to formation of superoxide
species (O2
). EPR spin-trapping experiments and plasmid-
DNA cleavage provide evidence of ROS formation.54,55 H2O2 can
be generated by dismutation. Cu+ is able to convert H2O2 to
OH radicals, while O2
 can also reduce Cu2+ to Cu+.56
On the other hand, there are copper(II) thiosemicarbazone
complexes with redox activity in a biologically relevant window
which neither induce generation of ROS nor show apoptotic
potential.8a,57
2.5 Antiproliferative activity, and cytostatic and cytotoxic potency
Results of MTT assay. The cell growth inhibition activity of
the proligands HL1–6 and their copper(II) complexes 1–6 against
four human cancer cell lines, namely lung adenocarcinoma
(A549), colon cancer (LS174), breast carcinoma (MDA-MB-453)
and normal bronchial epithelial cells (BEAS-2B), was deter-
mined by MTT assay. The proligands with phenyl substituents
at the terminal N atom of the thiosemicarbazide moiety,
HL3 and HL6, showed IC50 values o100 mM in LS174, and
MDA-MB-453 cell lines (Table 2) with slightly elevated cytotoxic
potency of the former structural isomer (HL3). All other inves-
tigated proligands did not reach IC50 in the investigated range
of concentrations up to 100 mM. The complexes 1, 2, 3, 5 and 6
showed IC50 values up to 35 mM. The highest cytotoxic effect
was observed for 5 in LS174 with IC50 = 13.7  0.5 mM. This
effect was slightly superior to that of reference compound
cisplatin (IC50 = 22.4  7.2 mM). The complexes 3 and 6 were
most active in A549 cells with IC50 values of 20.3  1.8 mM and
23.2  1.1 mM, respectively, and in MDA-MB-453 with IC50
values of 30.8  1.1 mM (a 2.4-fold increase of activity over that
of the proligand) and 18.9  1.1 mM (a 4.7-fold increase),
respectively, which is comparable with the IC50 value for
cisplatin as a positive control (26.2  5.4 mM and 13.5  2.6,
respectively). Therefore, A549 cells were chosen as a cell model
for further investigation of the mechanism of the antiprolifera-
tive action of 3 and 6 (vide infra). Regretably, the complexes 1–6
did not show any selectivity for cancer cells. In contrast,
complexes 3 and 4 showed a two to three times higher anti-
proliferative effect in normal BEAS-2B cells.
Taking into account the IC50 values for proligands HL
1–HL6
and their copper(II) complexes 1–6 in A549 and MDA-MB-453
Fig. 6 The cyclic voltammograms of 4 (black trace), 5 (red trace) and 6
(green trace) in DMSO/nBu4NPF6 at scan rate of 100 mV s
1.
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cell lines, complex formation with copper(II) increased the
cytotoxic potency of all investigated proligands. The attachment
of a methyl or phenyl group at the terminal N atom of the
thiosemicarbazide moiety slightly increased the cytotoxic
potency of the complexes. This increased in the following rank
order 1 E 2 o 3 and 4 o 5 o 6 in the A549 cell line. In the
MDA-MB-453 cell line the attachment of bulky groups increases
cytotoxicity in the following order 4 o 5 o 6, while in the
case of complexes 1–3 enhancement of cytotoxicity was not
observed.
Cell cycle analysis. The mechanism of cell growth inhibition
by complexes 3 and 6 was investigated via analysis of cell cycle
perturbations and apoptosis induction in A549 cells by flow
cytometry. The cell cycle analysis was performed after 24 h of
treatment at three diﬀerent drug concentrations IC50, 1.5IC50,
and 2IC50 (Fig. 8). Complex 3 decreased the percent of cells in
the G1 phase and increased the number of cells in S and G2
phases at all three concentrations, without any change in the
population of the Sub-G1 phase (cells with fragmented DNA).
Strong detachment of cells was revealed after treatment with
higher concentrations (1.5IC50 and 2IC50) of 3. Treatment with
6 did not induce any morphological changes. The decrease of
the percent of cells in the G1 phase and the increase of the
percent of cells in S and G2 phases were similar to those
observed for 3. The cisplatin as a reference compound induced
an increase of the percent of cells in the Sub-G1 phase (up to
30% with 2IC50 concentration), and a decrease of the percent of
cells in G1 and G2 phases, in accordance with the literature
data.59,60 The data of the cell cycle analysis point to the likely
diﬀerent mechanism of action of investigated complexes 3 and
6 compared to cisplatin in A549 cells.
Overall, both isomers revealed similar eﬀects on the cell
cycle in A549 cells after 24 h incubation. For comparison,
copper(II) complexes with 8-hydroxyquinoline-2-carboxaldehyde
thiosemicarbazones revealed dose-dependent cell growth
inhibition, S-phase cell cycle arrest and apoptosis of cisplatin-
resistant SK-N-DZ neuroblastoma cells.61 Other closely related
copper(II) compounds were found to cause cell cycle arrest in
the G2/M phase in human non-small cell lung cancer (NSCLC)
cell line A549.8a
Fig. 7 The cyclic voltammograms of 6 in DMSO/nBu4NPF6 at diﬀerent scan rates: (a) I = f (E) and (b) In1/2 = f (E), as well as the dependence of the
(c) cathodic and (d) anodic peak current on the square root of the scan rate.
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Further investigation of cell cycle perturbations induced by
the investigated complexes after prolonged drug exposure
(48 h) (Fig. 9) showed an increase of the percent of cells in
the Sub-G phase to 19% for 3 and 33% for 6 compared to the
control (only 3.3%).
Obviously, the decrease of the percent of cells in the G1
phase and the accumulation of cells in S and G2 phases after
24 h treatment, which continued after 48 h treatment, induced
cell demise.
Flow-cytometric analysis of apoptotic potential by annexin-
V-FITC/PI. In order to investigate the nature of cell death
induced by 3 and 6, annexin-V-FITC and propidium iodide
(PI) staining was performed. Apoptotic cell death, in most cell
types, is accompanied by a change in plasma membrane
structure by surface exposure of phospholipid phosphatidylserine
(PS), while the membrane integrity is retained.62,71 Surface
exposed PS can be detected by protein annexin-V.71 To distinguish
apoptotic cells from nonapoptotic cells, annexin-V staining is
usually combined with cell-impermeable dyes, such as propidium
iodide (PI). The incubation of A549 cells with 3 and 6 for 24 h and
IC50 concentrations did not induce PS externalisation (Fig. 10 and
Fig. S18, ESI†).
The majority of cells treated with 3, 6 and cisplatin for 24 h
preserved cell membrane integrity as over 80% of cells did stain
neither with annexin-V-FITC nor with PI. Only in the case of
cisplatin a higher percent of cells with damaged membranes
was detected (18% compared to control 3%). These results
indicate that after 24 h incubation with 3 and 6 at concentra-
tions equivalent to IC50, A549 cells remained alive.
As pointed out in cell cycle analysis as well, upon cell
collection after the treatment with 3 it was observed that the
cells became round and detached from the surface on a large
scale. Upon treatment with an IC50 concentration of 3, approxi-
mately 10% of cells became round and detached, while at a
1.5IC50 concentration of the drug all cells became round and
detached. Treatment with 6 at IC50 and 1.5IC50 concentrations
for 24 h did not induce any morphological changes. Hence,
further investigations with a higher concentration (2IC50) of
the investigated agent were conducted. The results showed the
same trend of morphological changes without PS externalisa-
tion (Fig. S19, ESI†). Extended incubation to 48 h showed
similar results (Fig. S20, ESI†). The majority of the cells treated
with 3 and 6 preserved cell membrane integrity with no PS
Table 2 Results of MTT assay for proligands HL1–6 and copper(II)
complexes 1–6 after 48 h treatment
IC50  SD [mM]
Cell line
Compound A549 MDA-MB-453 LS174 BEAS-2B
HL1 4100 4100 4100 4100
HL2 4100 4100 4100 4100
HL3 4100 74.0  1.8 33.6  2.3 33.8  1.1
HL4 4100 4100 4100 4100
HL5 4100 4100 4100 4100
HL6 4100 87.9  2.7 42.6  1.3 56.0  4.6
1 28.4  2.8 30.7  1.2 33.6  2.8 21.5  1.6
2 30.5  2.6 30.0  0.7 23.7  0.5 24.8  1.5
3 20.3  1.8 30.8  1.1 33.4  1.0 10.2  0.7
4 66.4  2.5 51.4  4.6 44.2  2.4 22.7  1.7
5 33.8  2.8 29.0  1.3 13.7  0.5 26.2  1.8
6 23.2  1.1 18.9  1.1 35.0  1.3 14.0  1.4
Cisplatin* 26.2  5.4 13.5  2.6 22.4  7.2 14.2  1.4
The sign (4) indicates that the IC50 value was not reached in the
examined range of concentrations (the sign is in front of the maximum
value of the concentration in the used range of concentrations).
* Results published previously.58
Fig. 8 Cell cycle analysis of A549 cancer cells after 24 h of exposure to 3 and 6 and cisplatin (CDDP). The concentrations of agents used for treatment
were concentrations corresponding to IC50, 1.5IC50 and 2IC50. The flow cytometric analysis was carried out after PI staining.
Fig. 9 Cell cycle analysis of A549 cancer cells after 48 h of exposure to
investigated complexes 3 and 6 and cisplatin (CDDP). The concentrations
of agent used for treatment were concentrations corresponding to IC50.
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externalisation. The percent of cells with damaged membranes
(dead cells) increased to about 12%, as compared to control
3%, while cisplatin was able to induce an increase of the
percent of apoptotic cells. Taking into account that apoptosis
is a stochastic event with variable induction and execution
kinetics,62 further analysis with variations in time and concen-
trations of treatment, as well as introduction of other methods,
is required to determine whether 3 and 6 have apoptotic
potential.
Results of morphological analysis of cell death. Fluorescence
microscopy after acridine orange/ethidium bromide (AO/EB)
staining was used to analyse morphological changes induced
by the investigated complexes. AO (green) is a vital dye, which
stains both live and dead cells, while EB (orange to red) only
Fig. 10 The presented dot plots combining annexin-V-FITC (FL1-height) and PI (FL2-height) fluorescence show the quantification of apoptosis in A549
cells treated with cisplatin (B), 3 (C) and 6 (D) as well as untreated cells (A). The cells were treated with IC50 concentrations of compounds for 24 h. The
viable cell population is in the lower left quadrant (annexin-VFITC/PI), the early apoptotic cells are in the lower right quadrant (annexin-V+/PI), the
late apoptotic cells are in the upper right quadrant (annexin-V+/PI+), and the dead cells are in the upper left quadrant (annexin-VFITC/PI+).
Fig. 11 Fluorescent micrographs presenting A549 cells: (A) the untreated cells used as a control and (B) cells treated with 3 and (C) cells treated with 6
for 24 h with concentrations corresponding to 2IC50. Cells stained with ethidium bromide (EB) and acridine orange (AO) were analysed with a fluorescent
microscope (Axio Observer Z1) by using AxioVision imaging software (Carl Zeiss MicroImaging GmbH). AO (green) is a vital dye, which stains both live and
dead cells. EB (orange to red) only stains cells that have lost membrane integrity.
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stains cells that have lost membrane integrity.63 The micro-
photographs of A549 cells stained by AO/EB, following 24 h
treatment with 3 and 6, are displayed in Fig. 11. Control cells
(non-treated cells) are dense, light-green coloured and elon-
gated with a spindle-shape (Fig. 11A). After 24 h treatment, with
a 2IC50 concentration of 3, cells started to lose their normal
morphology and became rounded, and reduced in size,
with still intact cell membranes, since cells incorporated only
AO (green fluorescence). Several early apoptotic cells with
condensed or fragmented chromatin were spotted. The number
of cells was markedly reduced compared to the control, as
many of them detached (Fig. 11B). At the same time complex 6
after 24 h treatment at a 2IC50 concentration induced only a
slight reduction of the number of cells compared to the control,
without noticeable morphological changes (Fig. 11C). These
results are in compliance with the results of apoptotic potential
by annexin-V-FITC and PI staining, as well as flow cytometric
analysis.
Whether this behaviour is due to the presence of dichloro-
acetate in investigated complexes, should be clarified in our
future investigations, which will require the synthesis of analogous
copper(II) complexes without dichloroacetate.
3 Conclusions
Six methyl imidazole-derived thiosemicarbazones and their
corresponding copper(II) complexes were synthesised and
characterised by NMR, IR, UV-vis spectroscopy, ESI-MS spectro-
metry, X-ray crystallography and elemental analysis. According
to NMR spectroscopic data, all proligands exist as geometric Z
and E isomers in a 1 : 1 molar ratio in DMSO solution except
HL2, for which the Z isomer is favoured (79%). Due to the fast
proton exchange, acid–base tautomerism of the imidazole ring
was observed. At higher pH values thione/thiol tautomerism of
the thiosemicarbazide moiety occurred in accordance with
solution equilibrium studies of other related thiosemicarbazones.
In the investigated pH range 2–12, two proton dissociation
constants were attributed to two proton donors, namely imida-
zole N2
0
H and hydrazine N4
0
H groups. At physiological pH the
proligands are present in neutral HL form.
All thiosemicarbazone ligands are coordinated to copper(II)
in a tridentate NNS manner in their neutral form and together
with dichloroacetate as a co-ligand form cationic complexes
[Cu(HL1–6)(CHCl2CO2)]
+ (in 1–6), which are counterbalanced by
another dichloroacetate anion building neutral ionic complexes,
which are isolated in the solid state. Copper(II) adopts distorted
square-planar (in 1, 4 and 5) or square-pyramidal (in 2, 3 and 6)
coordination geometry. According to electrochemical studies
the complexes 1–6 can undergo redox processes in a bio-
logically accessible window (–0.4 to +0.8 V vs. NHE).
The cell growth inhibition study showed that introduction of
a phenyl substituent at the terminal N atom of the thiosemi-
carbazide moiety of the proligands HL3 and HL6 enhances their
antiproliferative eﬃciency in LS174 and MDA-MB-453 cell lines
when compared to other proligands. In addition, the proligand
HL3 with the methyl group at position 2 of the imidazole ring
exhibited slightly better potency compared to its structural
isomer HL6 with the methyl group at position 5. Coordination
to copper(II) induced enhancement of the cytotoxic eﬀect of all
proligands in all investigated cell lines. In particular, the
complexes 3 and 6, both with phenyl substituted ligands at
the terminal N atom, revealed a 2.4- and 4.7-fold increase of
antiproliferative activity compared to their parent proligands in
the MDA-MB-453 cell line. Overall, according to the IC50 values,
the following rank orders of cytotoxic eﬃciency of the proligands
HL1–6 and their copper(II) complexes 1–6 could be established:HL1
EHL2EHL3o 1E 2o 3 andHL4EHL5EHL6o 4o 5o 6
in the A549 cell line, and HL1 E HL2 o HL3 o 1 E 2 E 3 and
HL4 E HL5 o HL6 o 4 o 5 o 6 in the MDA-MB-453 cell line.
The highest activity was observed in the cell line LS174 for 5
(IC50 =13.7  0.5 mM). This is slightly better than for cisplatin as a
positive control (IC50 = 22.4  7.2 mM). All investigated complexes
showed poor selectivity to cancer cells when compared to their
activity against normal human bronchial epithelial cells (BEAS-2B)
and were in this respect similar to cisplatin.
Even though 3 and 6 showed IC50 values (20 mM and 23 mM,
respectively) in A549 cells comparable to that for cisplatin
(26 mM), indicating similar cell growth inhibiting potential,
further insight into their mechanism of antiproliferative activity
revealed that these complexes probably act in a diﬀerent way than
cisplatin. MTT assay determines the number of viable cells via the
measurement of the activity of mitochondrial enzymes present
in metabolically active cells. Therefore, it cannot distinguish
between cytostatic and cytocidal eﬀects.69 Our investigation of
cell cycle, apoptotic potential and morphological analysis of
changes induced by 3 and 6 pointed to cytostatic rather than
cytotoxic eﬀects of investigated complexes with an important anti-
adhesion eﬀect of complex 3 on A549 cells. Even though cell cycle
analysis and annexin-V-FITC/PI staining indicate that there are no
major diﬀerences in the activity among these two complexes
regardless of the structural diﬀerences, the fluorescent micro-
scopy analysis revealed considerable diﬀerences in the activity of
these two isomeric complexes at least in the ‘‘time window’’ of
action/where the morphological changes take place. Further
investigations into the contribution of dichloroacetate to the
observed biological response of the cells to complexes 3 and 6
are underway in our laboratory and will be reported in due course.
4 Experimental section
4.1 Materials and methods
2-Methyl-1H-imidazole-4-carboxaldehyde, and 4-methyl-1H-
imidazole-5-carboxaldehyde were purchased from Acros Organics.
Thiosemicarbazide, 4-methylthiosemicarbazide and 4-phenylthio-
semicarbazide, dichloroacetic acid, copper(II) basic carbonate,
KOH, KCl, 4-(2-hydroxyethyl)-1-piperazineethane-sulfonic acid
(HEPES), and ethylenediaminetetraacetic acid (EDTA) were
purchased from Sigma Aldrich. Elemental analysis of HL1–6
was performed on a Carlo Erba microanalyser at the Micro-
analytical Laboratory of the University of Vienna. Electrospray
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ionisation mass spectrometry measurements were carried
out on a Bruker Esquire 3000 instrument (Bruker Daltonic,
Bremen, Germany) at the Mass Spectrometry Centre of the
Faculty of Chemistry of the University of Vienna. UV-vis spectra
were measured on a Perkin-Elmer Lambda 650 spectrophoto-
meter in the range 900–210 nm. The samples were prepared by
dissolving the compounds in MeOH or DMF (for complexes 2
and 3). Infrared spectra were recorded on Perkin-Elmer FT-IR
2000 instrument (4000–400 cm1) using an ATR unit or Bruker
Vertex 70 FT-IR spectrometer. NMR spectra were acquired on a
Bruker Avance III 500 MHz FT NMR spectrometer. All samples
were prepared by dissolving the compounds in (CD3)2SO.
4.2 Synthesis of proligands and copper(II) complexes
(E/Z)-2-((2-Methyl-1H-imidazol-4-yl)methylene)hydrazine-1-
carbothioamide (HL10.65H2O). A mixture of 2-methyl-1H-
imidazole-4-carboxaldehyde (1.10 g, 10 mmol) and thiosemi-
carbazide (0.91 g, 10 mmol) in EtOH (10 mL) was refluxed for
2 h and then cooled down to 0 1C. The pale yellow precipitate
was filtered oﬀ, washed with cold absolute EtOH (2 mL) and
dried in vacuo overnight. Yield: 1.75 g, 90%. Anal. calcd for
C6H9N5S0.65H2O (Mr 194.95), %: C, 36.97; H, 5.33; N, 35.92;
S, 16.45. Found, %: C, 36.99; H, 5.33; N, 35.50; S, 16.90.
1H NMR (500.10 MHz, (CD3)2SO, 25 1C) Z isomer: d 11.94 (s, 1H,
HN1
0
), 11.34 (s, 1H, HN4
0
), 8.17 (s, 1H, HaN
50), 7.86 (s, 1H, HC5),
7.82 (s, 1H, HbN
50), 7.21 (s, 1H, HC2), 2.30 (s, 3H, H3C
4) ppm. E
isomer: d 12.97 (s, 1H, HN4
0
), 12.50 (s, 1H, HN1
0
), 8.17 (s, 1H,
HaN
50), 7.79 (s, 1H,HbN
50), 7.55 (s, 1H,HC2), 7.12 (s, 1H,HC5), 2.38
(s, 3H, H3C
4) ppm. 13C{1H} NMR (125.76 MHz, (CD3)2SO, 25 1C)
Z isomer: d 177.92 (C6), 146.92 (C1), 133.48 (C5), 129.93 (C3), 128.91
(C2), 14.27 (C4) ppm. E isomer: d 178.10 (C6), 145.76 (C1), 135.65
(C3), 131.79 (C5), 122.07 (C2), 14.39 (C4) ppm. ESI-MS in MeOH
(positive):m/z 184 ([HL1 + H]+), 206 ([HL1 + Na]+). ESI-MS in MeOH
(negative): m/z 182 ([L1]). UV-vis in MeOH, l, nm (e, M1 cm1):
306 (29898), 315 (29614). IR (selected bands), ~n, cm1: 3553 (NH2),
3155 (Ar–H), 1613 (CQN), 785 (C–S).
(E/Z)-N-Methyl-2-((2-methyl-1H-imidazol-4-yl)methylene)-
hydrazine-1-carbothioamide (HL20.6H2O). To a solution of
2-methyl-1H-imidazole-4-carboxaldehyde (1.10 g, 10 mmol) in
dry ethanol (10 mL) 4-methylthiosemicarbazide (1.05 g,
10 mmol) in dry ethanol (10 mL) was added. The reaction
mixture was refluxed for 2 h and then cooled down to 0 1C.
The pale yellow precipitate was filtered oﬀ, washed with cold
ethanol (2 mL) and dried in vacuo overnight. Yield: 1.9 g, 92%.
Anal. calcd for C7H11N5S0.6H2O (Mr 208.07), %: C, 40.41;
H, 5.91; N, 33.66; S, 15.41. Found, %: C, 40.06; H, 5.88; N,
33.29; S, 15.33. 1H NMR (500 MHz, (CD3)2SO, 25 1C) Z isomer: d
11.99 (s, 1H, HN1
0
), 11.36 (s, 1H, HN4
0
), 8.26 (m, 1H, HN5
0
), 7.87
(s, 1H, HC5), 7.24 (s, 1H, HC2), 3.03 (d, 3H, H3C
7), 2.33 (s, 3H,
H3 C
4); E isomer, d, ppm: 13.01 (s, 1H, HN4
0
), 12.49 (s, 1H,
HN1
0
), 8.46 (m, 1H, HN5
0
), 7.54 (s, 1H, HC2), 7.11 (s, 1H, HC5),
2.97 (d, 3H, H3C
7), 2.38 (s, 3H, H3C
4) ppm. 13C{1H} NMR
(125.76 MHz, (CD3)2SO, 25 1C) Z isomer: d 177.81 (C
6), 146.99
(C1), 133.91 (C5), 130.96 (C3), 126.43 (C2), 31.00 (C7), 14.43 (C4)
ppm. E isomer: d 177.88 (C6), 145.74 (C1), 135.67 (C3), 131.10
(C5), 121.86 (C2), 31.26 (C7), 14.34 (C4) ppm. ESI-MS in MeOH
(positive): m/z 198 ([HL2 + H]+), 220 ([HL2 + Na]+). ESI-MS in
MeOH (negative): m/z 196 ([L2]). UV-vis in MeOH, l, nm
(e, M1 cm1): 306 (32 678), 316 (32 205). IR (selected bands),
~n, cm1: 3380 (NH2), 3152 (Ar–H), 1627 (CQN), 771 (C–S).
(E/Z)-2-((2-Methyl-1H-imidazol-4-yl)methylene)-N-phenyl-
hydrazine-1-carbothioamide (HL3H2O). A mixture of 2-methyl-
1H-imidazole-4-carboxaldehyde (1.1 g, 10 mmol) and 4-phenyl-
thiosemicarbazide (1.67 g, 10 mmol) in absolute EtOH (10 mL)
was refluxed for 2 h and then cooled down to 0 1C. The pale
yellow precipitate was filtered oﬀ, washed with cold ethanol
(2 mL) and dried in vacuo overnight. Yield: 2.60 g, 94%. Anal.
calcd for C12H13N5SH2O (Mr 277.35), %: C, 51.97; H, 5.45; N,
25.25; S, 11.56. Found, %: C, 52.10; H, 5.40; N, 24.97; S, 11.36.
1H NMR (500.10 MHz, (CD3)2SO, 25 1C) Z isomer: d 12.19 (s, 1H,
HN4
0
), 11.79 (s, 1H, HN1
0
), 9.94 (s, 1H, HN1
0
), 7.98 (s, 1H, HC5),
7.60 (s, 1H, HC8 or HC10), 7.58 (s, 1H, HC8 or HC10), 7.39
(m, 2H, HC9 and HC11), 7.21 (t, 1H, HC10), 2.33 (s, 3H, H3C
4)
ppm; E isomer: d 13.39 (s, 1H, HN4
0
), 12.56 (s, 1H, HN1
0
), 10.16
(s, 1H, HN5
0
), 7.66 (s, 1H, HC8 or HC10), 7,64 (s, 1H, HC8 or
HC10), 7.25 (s, 1H, HC5), 7.33 (m, 2H, HC9 and HC11), 7.15
(t, 1H, HC10), 2.4 (s, 3H, H3C
4) ppm. 13C{1H} NMR (125.76 MHz,
(CD3)2SO, 25 1C), Z isomer: d 175.68 (C
6), 139.35 (C7), 128.74
(C9), 128.74 (C11), 125.86 (C8), 125.86 (C12), 14.55 (C4) ppm.
E isomer: d 175.68 (C6), 145.91 (C1), 139.54 (C7), 135.47
(C3)132.02 (C5), 128.52 (C9), 128.52 (C11), 125.36 (C10), 125.18
(C8), 125.18 (C12), 122.5 (C2), 14.30 (C4) ppm. ESI-MS in MeOH
(positive): m/z 260 ([HL3 + H]+) 282 ([HL3 + Na]+). ESI-MS in
MeOH (negative): m/z 258 ([L3]). UV-vis in MeOH, l, nm
(e, M1 cm1): 208 (16 198), 317 (29 092). IR (selected bands),
~n, cm1: 3488 (NH2), 3133 (Ar–H), 1622 (CQN), 746 (C–S).
(E/Z)-2-((5-Methyl-1H-imidazol-4-yl)methylene)hydrazine-1-
carbothioamide (HL4). A mixture of 5-methyl-1H-imidazole-4-
carboxaldehyde (1.1 g, 10 mmol) and thiosemicarbazide
(0.91 g, 10 mmol) in dry ethanol (10 mL) was refluxed for
2 h and cooled down to 0 1C. The pale-yellow precipitate was
filtered oﬀ, washed with cold absolute ethanol (2 mL) and
dried in vacuo overnight. Yield 1.7 g, 93%. Anal. calcd for
C6H9N5S (Mr 183.24), %: C, 39.33; H, 4.95; N, 38.22; S, 17.50.
Found, %: C, 39.49; H, 4.98; N, 37.78; S, 17.15. 1H NMR
(500.10 MHz, (CD3)2SO, 25 1C), Z isomer: d 12.29 (s, 1H,
HN1
0
), 11.28 (s, 1H, HN4
0
), 8.13 (s, 1H, HaN5
0
), 7.89 (s, 1H,
HC5), 7.68 (s, 1H, HC1), 2.19 (s, 3H, H3C
4) ppm. E isomer: d
13.11 (s, 1H, HN4
0
), 11.28 (s, 1H, HN1
0
), 8.18 (s, 1H, HaN5
0
),
7.98 (s, 1H, HC1), 7.76 (s, 1H, HbN5), 7.21 (s, 1H, HC5), 2.36
(s, 3H, H3C
4) ppm. 13C{1H} NMR (125.76 MHz, (CD3)2SO,
25 1C), Z isomer: d 177.81 (C6), 137.48 (C1), 135.28 (C5),
13.20 (C4) ppm. E isomer: d 178.05 (C6), 131.43 (C1), 130.82
(C5), 9.50 (C4) ppm. ESI-MS in MeOH (positive): m/z 184 ([HL4
+ H]+) 206 ([HL4 + Na]+). ESI-MS in MeOH (negative): m/z 182
([L4]). UV-vis in MeOH, l, nm (e, M1 cm1): 208 (9607), 306
(28 298), 316 (27 558). IR (ATR, selected bands), ~n, cm1: 3388
(NH2), 3149 (Ar–H), 1593 (CQN), 710 (C–S).
(E/Z)-N-Methyl-2-((5-methyl-1H-imidazol-4-yl)methylene)-
hydrazine-1-carbothioamide (HL5). A mixture of 5-methyl-1H-
imidazole-4-carboxaldehyde (1.1 g, 10 mmol) and 4-methyl-3-
thiosemicarbazide (1.05 g, 10 mmol) in absolute ethanol
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(10 mL) was refluxed for 2 h and cooled down to 0 1C. The pale
yellow precipitate was filtered oﬀ, washed with cold absolute
ethanol (2 mL) and dried in vacuo overnight. Yield: 1.8 g, 91%.
Anal. calcd for C7H11N5S (Mr 197.26), %: C, 42.62; H, 5.62; N,
35.50; S, 16.26. Found, %: C, 42.71; H, 5.65; N, 35.21; S, 16.23.
1H NMR (500.10 MHz, (CD3)2SO, 25 1C), Z isomer: d 12.21
(s, 1H, HN1
0
), 11.31 (s, 1H, HN4
0
), 8.22 (m, 1H, HN5
0
), 7.90 (s,
1H, HC5), 7.71 (s, 1H, HC1), 3.03 (d, 3H, H3C
7), 2.24 (s, 3H,
H3C
4) ppm. E isomer: d 13.17 (s, 1H, HN4
0
), 12.66 (s, 1H,
HN1
0
), 8.43 (s, 1H, HN5
0
), 8.00 (s, 1H, HC1), 7.20 (s, 1H, HC5),
2.98 (d, 3H, H3C
7), 2.38 (s, 3H, H3C
4) ppm. 13C{1H} NMR
(125.76 MHz, (CD3)2SO, 25 1C), Z isomer: d 177.79 (C
6), 136.74
(C1), 135.20 (C5), 131.58 (C3), 31.00 (C7), 12.37 (C4) ppm.
E isomer: d 177.90 (C6), 130.13 (C5), 131.82 (C3), 31.29 (C7),
9.52 (C4) ppm. ESI-MS in MeOH (positive): m/z 198 ([HL5 +
H]+), 220 ([HL5 + Na]+). ESI-MS in MeOH (negative): m/z 196
([L5]). UV-vis in MeOH, l, nm (e, M1 cm1): 208 (9694),
308 (25 370), 318 (24 326). IR (selected bands), ~n, cm1: 3151
(Ar–H), 1620 (CQN), 755 (C–S).
(E/Z)-2-((5-Methyl-1H-imidazol-4-yl)methylene)-N-phenyl-
hydrazine-1-carbothioamide (HL6). A mixture of 5-methyl-
1H-imidazole-4-carboxaldehyde (1.10 g, 10 mmol) and 4-phenyl-
thiosemicarbazide (1.67 g, 10 mmol) in dry EtOH (10 mL) was
refluxed for 2 h and then cooled down to 0 1C. The pale yellow
precipitate was filtered oﬀ, washed with cold EtOH (2 mL) and
dried in vacuo overnight. Yield: 2.4 g, 93%. Anal. calcd for
C12H13N5S (Mr 259.33), %: C, 55.58; H, 5.05; N, 27.01; S, 12.36.
Found, %: C, 55.46; H, 5.06; N, 26.69; S, 12.13. 1H NMR
(500 MHz, (CD3)2SO, 25 1C), Z isomer: d 12.42 (s, 1H, HN
10),
11.72 (s, 1H, HN4
0
), 9.93 (s, 1H, HN5
0
), 8.11 (s, 1H, HC5), 7.78 (s,
1H, HC1), 7.62 (d, 2H, HC8 and HC12), 7.41–7.36 (m, 2H, HC9
and HC12), 7.21 (t, 1H, HC10), 2.26 (s, 3H, H3C
4) ppm. E isomer:
d 13.50 (s, 1H, HN4
0
), 12.74 (s, 1H, HN1
0
), 10.14 (s, 1H, HN5
0
),
7.95 (s, 1H, HC1), 7.66 (d, 2H, HC8 and HC12), 7.36–7.31 (m, 3H,
HC9, HC12 and HC5), 7.16 (t, 3H, HC10), 2.41 (s, 3H, H3C
4).
13C{1H} NMR (125.76 MHz, (CD3)2SO, 25 1C), Z isomer: d 175.41
(C6), 139.32 (C7), 137.16 (C1), 128.71 (C9 and C11), 125.64 (C10),
125.43 (C8 and C12), 12.60 (C4) ppm. E isomer: d 175.70 (C6),
139.53 (C7), 135.46 (C1), 131.82 (C3), 131.01 (C5), 132.32 (C2),
131.72 (C3), 128.49 (C9 and C11), 125.35 (C10), 125.20 (C8 and
C12), 9.57 (C4) ppm. ESI-MS in MeOH (positive): m/z 260 ([HL6 +
H]+), 282 ([HL6 + Na]+). ESI-MS in MeOH (negative): m/z 258
([L6]). UV-vis in MeOH, l, nm (e, M1 cm1): 207 (18 839), 318
(31 074). IR (selected bands), ~n, cm1: 3321 (NH2), 3117 (Ar–H),
1611 (CQN), 740 (C–S).
[Cu(HL1)(CHCl2CO2)]CHCl2CO2 (1). To a solution of HL
1
(0.19 g, 1.0 mmol) in ethanol (15 mL) was added dropwise
under stirring a solution of Cu2(OH)2CO3 (0.12 g, 0.5 mmol)
and dichloroacetic acid (0.19 g, 1.0 mmol) in water (15 mL). The
reaction mixture was refluxed at 70 1C for 30 min, cooled down,
and allowed to stand for 3–4 days at room temperature. Slow
solvent evaporation resulted in precipitation of a green product,
which was filtered off, washed with ethanol (2  2 mL) and dried
in vacuo. X-ray diffraction quality single crystals of 1 were obtained
by re-crystallisation in ethanol. Yield: 0.44 g, 88%. ESI-MS in
MeOH (positive): m/z 245 ([CuII(L1)]+), 619 ([CuII2(L
1)2(CHCl2CO2)]
+).
ESI-MS inMeOH (negative):m/z 373 ([CuII(L1–H)(CHCl2CO2)]
), 617
([CuII2(L
1–H)2(CHCl2CO2)]
). UV-vis in MeOH, l, nm (e, M1 cm1)
203 (8075), 282 (7276), 335 (7837), sh 363 (5100) 632 (158). IR
(selected bands), ~n, cm1: 1644 (CQN), 1576 (COOas), 1356 (COOs),
701 (C–S).
[Cu(HL2)(CHCl2CO2)(H2O)]CHCl2CO2H2O (2). To a solution
ofHL2 (0.2 g, 1.0 mmol) in ethanol (15 mL) was added dropwise
under stirring a solution of Cu2(OH)2CO3 (0.12 g, 0.5 mmol)
and dichloroacetic acid (0.19 g, 1.0 mmol) in water (15 mL). The
reaction mixture was refluxed at 70 1C for 30 min, cooled down,
and allowed to stand for 3 days at room temperature. Slow
solvent evaporation resulted in precipitation of a green solid.
This was filtered oﬀ, washed with ethanol (2  2 mL) and dried
in vacuo overnight. X-ray diﬀraction quality crystals of 2
were obtained by re-crystallisation in ethanol. Yield: 0.42 g,
81%. ESI-MS in MeOH (positive): m/z 259 ([CuII(L2)]+), 647
([CuII2 (L
2)2(CHCl2CO2)]
+). ESI-MS in MeOH (negative): m/z 387
([CuII(L2–H)(CHCl2CO2)]
), 645 ([CuII2 (L
2–H)2(CHCl2CO2)]
).
UV-vis in DMF, l, nm (e, M1 cm1) 293 (17 287), 353
(14 197), 587 (233). IR (selected bands), ~n, cm1: 1630 (CQN),
1570 (COOas), 1353 (COOs), 720 (C–S).
[Cu(HL3)(CHCl2CO2)(EtOH)]CHCl2CO2 (3). To a solution of
HL3 (0.28 g, 1.0 mmol) in ethanol (15 mL) a solution of
Cu2(OH)2CO3 (0.12 g, 0.50 mmol) and dichloroacetic acid
(0.19 g, 1.0 mmol) in water (15 mL) was added dropwise under
stirring. The reaction mixture was refluxed at 70 1C for 30 min.,
cooled down, and allowed to stand for 3 days at room tempera-
ture. Slow solvent evaporation resulted in precipitation of
a green product. This was filtered oﬀ, washed with ethanol
(2  2 mL) and dried in vacuo. X-ray diﬀraction quality crystals
of 3 were obtained by re-crystallisation in ethanol. Yield: 0.55 g,
92%. ESI-MS in MeOH (positive): m/z 321 ([CuII(L3)]+), 771
([CuII2 (L
3)2(CHCl2CO2)]
+). ESI-MS in MeOH (negative): m/z 449
([CuII(L3–H)(CHCl2CO2)]
), 769 ([CuII2 (L
3–H)2(CHCl2CO2)]
).
UV-vis in DMF, l, nm (e, M1 cm1) 339 (21 862), 363
(21 442), 577 (253). IR (selected bands), ~n, cm1: 1612 (CQN),
1739 (COOas), 1594 (COOas), 1348 (COOas), 1280 (COOs), 698 (C–S).
[Cu(HL4)(CHCl2CO2)]CHCl2CO2 (4). To a solution of HL
4
(0.18 g, 1.0 mmol) in ethanol (15 mL) a solution of Cu2(OH)2CO3
(0.12 g, 0.5 mmol) and dichloroacetic acid (0.19 g, 1.0 mmol) in
water (15 mL) was added dropwise under stirring. The reaction
mixture was refluxed at 70 1C for 30 min, cooled down,
and allowed to stand for 4 days at room temperature. Slow
solvent evaporation generated a green product. This was
filtered oﬀ, and washed with ethanol (2  2 mL). X-ray diﬀrac-
tion quality crystals of 4 were obtained by re-crystallisation
in ethanol. Yield: 0.47 g, 94%. ESI-MS in MeOH (positive):
m/z 245 ([CuII(L4)]+), 619 ([CuII2 (L
4)2(CHCl2CO2)]
+). ESI-MS in
MeOH (negative): m/z 373 ([CuII(L4–H)(CHCl2CO2)]
), 617
([CuII2 (L
4–H)2(CHCl2CO2)]
). UV-vis in MeOH, l, nm (e, M1
cm1): 202 (8119), sh 235 (4312), 283 (6874), 337 (8344), sh
367 (5245), 628 (319). IR (selected bands), ~n, cm1: 1619 (CQN),
1726 (COOas, coordinated), 1518 (COOas), 1354 (COOs), 1248
(COOs), 709 (C–S).
[Cu(HL5)(CHCl2CO2)]CHCl2CO2EtOH (5). To a solution
of HL5 (0.20 g, 1.0 mmol) in ethanol (15 mL) a solution
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of Cu2(OH)2CO3 (0.12 g, 0.5 mmol) and dichloroacetic acid
(0.19 g, 1.0 mmol) in water (15 mL) was added dropwise under
stirring. The reaction mixture was refluxed at 70 1C for 30 min.,
cooled down, and allowed to stand for 3 days at room tempera-
ture. By slow evaporation of the solvent at room temperature
green product 5 was isolated. X-ray diﬀraction quality crystals
of 5 were obtained by re-crystallisation in ethanol. Yield:
0.51 g, 91%. ESI-MS in MeOH (positive): m/z 259 ([CuII(L5)]+),
647 ([CuII2 (L
5)2(CHCl2CO2)]
+). ESI-MS in MeOH (negative): m/z
387 ([CuII(L5–H)(CHCl2CO2)]
), 645 ([CuII2 (L
5–H)2(CHCl2CO2)]
).
UV-vis in MeOH, l, nm (e, M1 cm1): 205 (12 823), 237 (6430),
292 (10 420), 338 (13 225), sh 369 (8908), 626 (174). IR (selected
bands), ~n, cm1: 1624 (CQN), 1523 (COOas), 1336 (COOs), 710
(C–S).
[Cu(HL6)(CHCl2CO2)(H2O)]CHCl2CO2EtOH (6). To a
solution of HL6 (0.26 g, 1.0 mmol) in ethanol (15 mL) a solution
of Cu2(OH)2CO3 (0.12 g, 0.5 mmol) and dichloroacetic acid
(0.19 g, 1.0 mmol) in water (15 mL) was added dropwise
under stirring. The reaction mixture was refluxed at 70 1C for
30 min., cooled down, and allowed to stand for 4 days at room
temperature. Slow solvent evaporation resulted in separation
of a green product. This was filtered oﬀ, washed with ethanol
(2  2 mL) and dried in vacuo. X-ray diﬀraction quality crystals
of 6 were obtained by re-crystallisation in ethanol. Yield: 0.55 g,
94%. ESI-MS in MeOH (positive): m/z 321 ([CuII(L6)]+), 771
([CuII2 (L
6)2(CHCl2CO2)]
+). ESI-MS in MeOH (negative): m/z 449
([CuII(L6–H)(CHCl2CO2)]
), 769 ([CuII2 (L
6–H)2(CHCl2CO2)]
).
UV-vis in MeOH, l, nm (e, M1 cm1): 204 (23 388), 230
(16 106), 346 (19 816), 360 (18 841), sh 381 (14 783), 614 (205).
IR (selected bands), ~n, cm1: 1627 (CQN), 1595 (COOas), 1350
(COOs), 692 (C–S).
4.3 Crystallographic structure determination
X-ray diﬀraction measurements were carried out on a Bruker X8
APEXII CCD diﬀractometer using graphite monochromated
MoKa radiation (l = 0.71073 Å) at 120 K. The data were
processed using SAINT software.64 The structures were solved
by direct methods using Olex265 and refined by full-matrix
least-squares on weighted F2 with SHELXL 201566 using an
anisotropic model for non-hydrogen atoms. All H atoms were
inserted in idealised positions (dCH = 0.96 Å) using the riding
model with their isotropic displacement parameters fixed at
120% of their riding atom. Positional parameters of the H
attached to O or N atoms were obtained from diﬀerence Fourier
syntheses and verified by the geometric parameters of the
corresponding hydrogen bonds. The molecular plots were
obtained using the Olex2 program. The crystallographic data
and refinement details are quoted in Table 3, while bond
lengths and bond angles are summarised in Tables S1–S7,
ESI.† CCDC – 1577585 for 1, 1845470 for 2, 1845471 for 3,
1845472 for 4, 1845473 for 5 and 1845474 for 6 contain the
supplementary crystallographic data for this contribution.†
4.4 Spectrophotometric measurements (solution equilibrium
studies)
A Hewlett Packard 8452A diode array spectrophotometer was
used to record the UV-vis spectra in the interval 200–800 nm.
The path length was 1 cm. Protonation constants (b(HiL)) of the
ligands HL1 and HL4 and the individual spectra of the species
in the various protonation states were calculated by the
computer program PSEQUAD.67 Spectrophotometric titrations
were performed on samples containing the ligands at 49 mM
Table 3 Crystal data and details of data collection for 1–6
Compound 1 2 3 4 5 6
Empirical formula C10H11Cl4CuN5O4S C11H17Cl4CuN5O6S C18H21Cl4CuN5O5S C10H11Cl4CuN5O4S C13H19Cl4CuN5O5S C18H23Cl4CuN5O6S
Fw 502.64 552.70 624.81 502.64 562.73 642.83
T [K] 120 120 120 120 120 120
Space group P21/c P21/c P21/n P21/c P%1 P21/n
a [Å] 13.8439(9) 7.5477(3) 9.5794(11) 10.0981(7) 8.9820(6) 9.4329(4)
b [Å] 11.9326(9) 17.3408(6) 17.6082(16) 21.8935(15) 9.8523(6) 20.2920(8)
c [Å] 11.6222(7) 15.7754(6) 15.4996(15) 17.1161(12) 13.4982(9) 14.1277(5)
a [1] 90.0 90.00 90.00 90.00 103.683(3) 90.00
b [1] 110.322(3) 95.6740(10) 105.502(4) 106.756(3) 94.647(3) 99.180(2)
g [1] 90.0 90.00 90.00 90.00 110.613(3) 90.00
V [Å3] 1800.4(2) 2054.62(13) 2519.3(4) 3623.4(4) 1068.42(12) 2669.58(18)
Z 4 4 4 8 2 4
rcalcd [g cm
3] 1.854 1.787 1.647 1.843 1.749 1.599
m [mm1] 1.949 1.724 1.414 1.937 1.656 1.339
Crystal size [mm] 0.08  0.08  0.15 0.20  0.15  0.12 0.20  0.12  0.10 0.27  0.15  0.15 0.20  0.15  0.15 0.22  0.12  0.12
2Y range 4.64 to 52.74 4.698 to 52.74 4.52 to 50.06 4.22 to 50.08 4.6 to 50.84 4.02 to 49.2
Reflections collected 35 405 30 340 29 389 82 072 67 667 61 193
Independent reflections 3672 [Rint = 0.0243] 4197 [Rint = 0.0421] 4441 [Rint = 0.0627] 6238 [Rint = 0.0332] 3924 [Rint = 0.0243] 4554 [Rint = 0.0431]
Data/restraints/
parameters
3672/3/236 4197/0/255 4441/4/312 6328/0/453 3924/0/322 4454/3/318
R1
a 0.0231 0.0270 0.0382 0.0223 0.0163 0.0240
wR2
b 0.0561 0.0626 0.0888 0.0524 0.0427 0.0575
GOFc 1.037 1.056 1.034 1.028 1.060 1.022
0.37/0.33 0.67/0.46 1.03/0.58 0.49/0.50 0.35/0.33 0.43/0.32
a R1 =
P
||Fo| |Fc||/
P
|Fo|.
b wR2 = {
P
[w(Fo
2  Fc2)2]/
P
[w(Fo
2)2]}1/2. c GOF = {
P
[w(Fo
2 Fc2)2]/(n  p)}1/2, where n is the number of reflections and
p is the total number of parameters refined.
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concentration using a KOH solution in the presence of 0.1 M
KCl at 25.0  0.1 1C in the pH range from 2 to 12. An Orion
710A pH-meter equipped with a Metrohm combined electrode
(type 6.0234.100) and a Metrohm 665 Dosimat burette were
used for the pH-metric titrations. The electrode system
was calibrated to the pH = log[H+] scale by means of blank
titrations (HCl vs. KOH) according to the suggested method.68
The average water ionisation constant (pKw) is 13.76  0.05.
Argon was also passed over the solutions during the titrations.
Complex formation of HL1 and HL4 with copper(II) was
studied by the methods of molar ratio and continuous variation
at pH 4.07. Copper(II) stock solution was prepared by
the dissolution of CuCl2 in water and its concentration was
determined by complexometry with EDTA. For the constant
pH value of the samples an acetic acid/acetate buﬀer solution
was used. The concentration of the ligand or the metal ion was
constant (40 mM), while that of the other component was varied
in the case of the molar ratio method. In addition, various
metal-to-ligand ratios were also used, while the sum of the
concentrations of the metal ion and the ligand was constant
(100 mM). The conditional stability constants (b0) of the inves-
tigated complexes were calculated at pH 4.07 based on the
spectral changes via the displacement reaction with EDTA.
In the competition experiments the samples contained 50 mM
copper(II), and 50 mM ligand HL1 or HL4, and the concentration
of EDTA was varied in the range from 0 to 72 mM. The
conditional stability constants of the metal complexes
(b0 (CuL)) and the individual spectra of the species were
calculated by the computer program PSEQUAD.67 The overall
stability constants (b) of the complexes [CuL]+ were calculated
from the conditional stability constants: b(CuL) = b0(CuL)  aH,
where aH = 1 + [H
+]  b(HL) + [H+]2  b(H2L)+ and [H+] =
104.07 M.
4.5 Electrochemistry measurements
Cyclic voltammetric experiments for 1–6 (c1–6 = 10
3 M) in
DMSO (SeccoSolv max. 0.025% H2O, Merck) using nBu4NPF6
(puriss quality from Fluka; dried under reduced pressure
at 70 1C for 24 h before use, c = 0.1 M) as a supporting
electrolyte, were performed under an argon atmosphere in a
one-compartment electrochemical cell with platinum wire as
working and counter electrodes, and silver wire as a pseudo-
reference electrode. Ferrocene purchased from Sigma Aldrich
was used as the internal potential standard without further
purification. All potentials in voltammetric studies were quoted
vs. the ferricenium/ferrocene (Fc+/Fc) redox couple and controlled
by using a Heka PG310USB potentiostat (Lambrecht, Germany,
with the PotMaster 2.73 software package). Digital simulations of
cyclic voltammograms were performed via DigiElch Professional
software (version DigiElch8, Gamry Instruments, USA).
4.6 Antiproliferative activity (cell lines, culture conditions and
MTT assay)
Cell lines and culture conditions. The human lung adeno-
carcinoma cells (A549), human breast cancer cells (MDA-MB-453),
human colon cancer cells (LS174) and normal human bronchial
epithelial cells (BEAS-2B) were maintained as monolayer cultures
in the Roswell Park Memorial Institute (RPMI) 1640 nutrient
medium (Sigma Chemicals Co, USA). The RPMI 1640 nutrient
medium was prepared in sterile ionised water, and supplemented
with penicillin (192 IU mL1), streptomycin (200 mg mL1),
HEPES (25 mM), L-glutamine (3 mM), and heat-inactivated fetal
calf serum (FCS; 10%, pH 7.2). The cells were grown at 37 1C in
CO2 (5%) and humidified in air atmosphere, by twice weekly
subculture.
MTT assay. The antiproliferative activity of the compounds
was determined by using 3-(4,5-dimethylthiazol-yl)-2,5-diphenyl-
tetrazolium bromide (MTT, Sigma Aldrich) assay.69 Cells were
seeded into 96-well cell culture plates (Thermo Scientific Nunc)
in an appropriate density for each cell line. After 24 h of growth,
cells were exposed to the serial dilutions of the tested com-
pounds. The compounds were dissolved in dimethyl sulfoxide
(DMSO) and afterwards diluted with the nutrient medium to
the desired final concentrations. The amount of DMSO in the
prepared solutions wasr1%. Each concentration was tested in
triplicate. After an incubation period of 48 h, MTT solutions
(20 mL, 5 mg mL1 in phosphate buﬀer solution, pH 7.2) were
added to each well. Samples were incubated at 37 1C with CO2
(5%) in a humidified atmosphere for 4 h. Formazan crystals
were dissolved in sodium dodecyl sulfate (SDS; 100 mM, 10%).
Absorbance values were recorded after 24 h with an ELISA
reader (ThermoLabsystem Multiskan EX 200–240 V) at the
wavelength of 570 nm. The IC50 values, defined as the concen-
trations of the compound causing 50% cell growth inhibition,
were estimated from the dose–response curves.
Cell cycle analysis. The analysis of the cell cycle phase
distribution was performed by flow cytometric analysis of the
DNA content in fixed A549 cells, after staining with propidium
iodide (PI).70 Cells were seeded at a density of 2  105 cells per
well, into 6-well plates (Thermo Scientific Nunct), in 2 mL of
the nutrition medium. Cells were continually exposed to the
investigated complexes 3 and 6 or cisplatin at concentrations
corresponding to IC50, 1.5IC50, and 2IC50 for 24 h treatment
and with IC50 concentrations for 48 h treatment. Control cells
were incubated only in a nutrient medium. After continuous
treatment, all cells (detached and adherent) were collected,
washed with phosphate-buﬀered saline (PBS), and fixed over-
night in 70% ethanol. After fixation, cells were washed with
PBS, and incubated with RNaseA (1 mg mL1) at 37 1C for
30 min. Just before flow cytometric analysis, cells were stained
with PI, at a concentration of 400 mg mL1. The cell cycle phase
distribution was investigated using a fluorescence activated cell
sorter (FACS) Calibur Becton Dickinson flow cytometer and
analysed by Cell Quest computer software.
Mechanism of cell death: analysis of apoptotic potential by
annexin-V-FITC and PI staining. Flow cytometric analysis of the
potential of 3, 6 and cisplatin (reference compound) to induce
apoptosis in A549 cells was performed using an annexin-V-FITC
apoptosis detection kit, according to the manufacturer’s
instructions (BD Biosciences). The A549 cells (2  105) were
seeded into 6-well plates (Thermo Scientific Nunct), in 2 mL of
RPMI medium. After 24 h of growth, cells were treated with
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complexes or cisplatin for 24 or 48 h. After treatment, cells were
washed with ice-cold PBS and then resuspended in 200 mL
binding buﬀer (10 mM HEPES/NaOH pH 7.4, 140 mM NaCl,
2.5 mM CaCl2). 100 mL of cell suspension (10
5 cells) was
transferred to a 5 mL culture tube and mixed with 5 mL of
annexin V-FITC and 5 mL of PI.71 After incubation for 15 min, at
25 1C in the dark, 400 mL of binding buﬀer was added to each
tube and analysed using a FACS Calibur Becton-Dickinson flow
cytometer and Cell Quest computer software. A minimum of
10 000 cells were analysed per sample.
Morphological analysis of cell death by fluorescent micro-
scopy: A549 cells (1  104) were seeded into 6-well plates
(ThermoScientificNunct) in 2 mL of nutrient medium. After
24 h of growth, cells were exposed to complexes 3 and 6, at
2IC50 concentrations. Following 24 h treatment, cells were
stained with ethidium bromide (5 mg mL1) and acridine
orange (1.5 mg mL1), according to the procedure reported
elsewhere,72 and immediately after, observed under the fluor-
escent microscope Axio Observer Z1, using AxioVision imaging
software (Carl Zeiss MicroImaging GmbH).
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